Total de visites
Visites | |
---|---|
VHIO ... | 711 |
Total de visites per mes
d’octubre 2023 | de novembre 2023 | de desembre 2023 | de gener 2024 | de febrer 2024 | de març 2024 | d’abril 2024 | |
---|---|---|---|---|---|---|---|
VHIO ... | 25 | 15 | 12 | 19 | 27 | 22 | 29 |
Visites per país
Visites | |
---|---|
Espanya | 507 |
Estats Units | 60 |
França | 25 |
Suècia | 19 |
Irlanda | 15 |
Xina | 7 |
Costa d'Ivori | 5 |
Regne Unit | 5 |
Corea del Sud | 4 |
Singapur | 4 |
Visites per ciutat
Visites | |
---|---|
Barcelona | 263 |
Capellades | 60 |
Sabadell | 20 |
Dublin | 15 |
Sant Feliu de Llobregat | 14 |
Chandler | 12 |
L'Hospitalet de Llobregat | 12 |
Molins de Rei | 11 |
Ashburn | 9 |
Terrassa | 9 |
Documents més visitats
Visites | |
---|---|
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication | 291 |
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial | 230 |
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy | 221 |
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer | 204 |
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights | 203 |
New clinical trial designs in the era of Precision Medicine | 201 |
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer | 201 |
Cancer Core Europe: A translational research infrastructure for a European mission on cancer | 196 |
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial | 194 |
BRCA2 and Other DDR Genes in Prostate Cancer | 192 |